Abstract
Chemotherapy-induced nausea and vomiting (CINV) has tremendous negative impact on daily life of cancer patients and their quality of life. In this article we analyzed current clinical guidelines in preventive measures and treatment of CINV as well as efficacy of recommended standard regimens for CINV prevention in patients receiving high emetogenic chemotherapy (HEC). We summarized existing data about olanzapine – affordable antipsychotic agent with potent antiemetogenic activity which is quite useful for CINV prophylaxis in patients receiving HEC. We highlighted possible future directions for research of olanzapine in oncology and reasons that preclude integration of this drug in routine clinical practice in Russia.
Highlights
We summarized existing data about olanzapine – affordable antipsychotic agent with potent antiemetogenic activity which is quite useful for Chemotherapy-induced nausea and vomiting (CINV) prophylaxis in patients receiving high emetogenic chemotherapy (HEC)
Несмотря на отсутствие регистрации оланзапина в США как средства профилактики и лечения ТиР, ASCO и NCCN включили его в свои клинические рекомендации по антиэметогенной терапии [3, 38]
Summary
· Препараты с минимальным эметогенным потенциалом (
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
